June 25, 2025 Sweden
Diamyd Medical´s vd Ulf Hannelius presenterar bolagets Delårsrapport 3 och nuvarande status i bolaget. Delårsrapporten publicerades den 25 juni 2025. Producerat i samarbete med G&W Fondkomission.
|
June 19, 2025 Sweden
Diamyd Medical featured in Insights Accelerated, the newsletter from Stockholm-based consultancy Ventures Accelerated published on June 17th 2025. Read the article here
|
June 4, 2025 Sweden
SwedenBIO’s Working Group for Business Strategy, in collaboration with EY, hosted a seminar focused on how Swedish life science companies can successfully navigate entry into the U.S. market.
Ulf Hannelius, President and CEO of Diamyd Medical, contributed with perspectives on the company’s experience engaging with the FDA and navigating the regulatory landscape surrounding their application processes.
The seminar was recorded on Monday, June 2, 2025. Read the article on the seminar
|
June 2, 2025 Sweden
I avsnittet ger Ludvig Svensson en inblick i Diamyd Medicals internationella Fas 3-studie med tidig avläsning i mars 2026. Podden tar upp möjligheter och risker, samt vad investerare bör ha på radarn framöver. Lyssna här
|
May 8, 2025 Sweden
Styrelseordförande Anders Essen-Möller och vd Ulf Hannelius kommenterar kapitalanskaffningen och de intensifierade förberedelserna inför den kommande avläsningen av fas 3-studien DIAGNODE-3.
|